Cibus Prices $27.5 Mln Public Offering To Advance Gene-Edited Rice Traits

Cibus, Inc. (CBUS) has priced its public offering of 15,714,285 shares of Class A Common Stock at $1.75 per share, including a significant purchase by the Chairman of the Board, projecting gross proceeds of approximately $27.5 million. The offering, expected to close around June 6, 2025, aims to fund the development of weed management traits in rice and support general corporate purposes as the company seeks long-term financing. Following the announcement, CBUS is currently trading down 31.3814% at $1.6194 on the Nasdaq Capital Market.

Analysis

Cibus, Inc. (CBUS) has priced a public offering of 15,714,285 Class A Common Shares at $1.75 per share, intending to generate gross proceeds of approximately $27.5 million before deductions. These funds are earmarked for the advancement of Cibus's weed management productivity traits in rice, general corporate purposes, and working capital, particularly as the company seeks more comprehensive long-term financing. A notable aspect of the offering is the Chairman of the Board's purchase of 5,714,286 shares, representing over a third of the shares offered. Despite this insider participation, the market's response has been strongly negative, reflected in a -0.7 sentiment score for CBUS. The company's stock price plummeted 31.3814% to $1.6194 on the Nasdaq Capital Market, a level now below the $1.75 offering price, signaling significant investor concern over dilution or the offering's terms. The transaction is expected to close around June 6, 2025.

Key Decisions for Investors

• Investors should weigh the considerable shareholder dilution, underscored by the stock's fall to $1.6194 (below the $1.75 offering price), against the critical need for $27.5 million to advance Cibus's agricultural biotechnology pipeline.
• The Chairman's acquisition of over a third of the offered shares merits attention as a potential, albeit contrarian, signal of long-term confidence amidst pronounced negative market sentiment.
• Closely scrutinize Cibus's deployment of the new capital towards its rice weed management program and its progress in securing sustainable long-term financing, as this offering appears to be a bridging measure.
• Re-evaluate positions considering the depressed share price post-announcement, the specific R&D catalysts funded by this raise, and the high-risk, high-reward nature inherent in development-stage biotechnology firms.